2022-08-12 | NDAQ:ACER | Press Release | Acer Therapeutics Inc.
(2022-08-12 | NDAQ:ACER) Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Stay updated with breaking news from Pharma Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(2022-08-12 | NDAQ:ACER) Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
GuruFocus Article or News written by PurpleRose and the topic is about:
GENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER)
Investegate announcements from 4d Pharma PLC, Publication of Joint Administrators' Proposals
Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100 (Aviptadil) 03-Aug-2022 / 07:00 CET/CEST Release